CME

Host: Carlos M. de Castro, MD

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly diagnosed patients receive any PNH-specific treatment. Moreover, up to 20% of patients treated with C5 inhibitors continue to experience clinically significant extravascular hemolysis, leading to residual anemia and its complications. Thus, several new and novel complement inhibitors have been developed and approved. In this activity, Dr. Carlos de Castro reviews the diagnostic criteria for PNH and best practices for the selection of optimal treatment regimens.

Host: Aditya Bardia, MD, MPH

The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews challenges in treating HR+, HER2- MBC, the role of TROP2-directed ADCS, and how to tailor therapy for individual patients.

Host: Tycel Phillips, MD

Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.

Guest: Fernando López-Ríos, MD, PhD

Guest: Christian Rolfo, MD, PhD

Guest: Charlie Gourley, MD, PhD

In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers.

Topics of conversation include the following:

• An overview of challenges related to HER2 immunohistochemistry, guidance, and interpretation of the results
• Targeting HER2 in lung cancer: where does IHC testing fit in?
• Ovarian cancer: challenges and considerations for HER2 IHC testing

Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer.

The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Guest: Marilyn Yuanxin Ma Bui, MD, PhD

Guest: Anne Vincent-Salomon, MD

With the availability of HER2-directed therapies, it’s important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate biomarker assessment and explores the impact this may have on patient outcomes.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Host: Rishi Wadhera, MD, MPP, Mphil

This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.

Guest: Vera Bril, MD

Guest: Nicholas J. Silvestri, MD

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

Guest: Vera Bril, MD

Guest: Hans Katzberg, MD

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

Guest: Vera Bril, MD

Guest: Hans Katzberg, MD

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

Guest: Vera Bril, MD

Guest: Hans Katzberg, MD

While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.